Clinical trials: Viremia
Chronic Hepatitis B
Treatment of Persistent Viremia (Virus in Blood) in Chronic Hepatitis B Subjects Already Receiving Adefovir Dipivoxil
This study explores the efficacy, safety and tolerability of tenofovir DF (TDF) 300 mg once daily monotherapy versus the combination of emtricitabine 200 mg plus tenofovir DF 300 mg (FTC/TDF) once daily in subjects currently…
- Trial name
- NCT00307489
- Testing
- tenofovir DF, emtricitabine /tenofovir DF
- Where
- 28 sites in United States, France and 2 more
- Volunteers
- 106 people
- Sponsor
- Gilead Sciences
Polyomavirus Infections, BK Viremia
Prevalence of BK Viremia in Simultaneous Liver-Kidney Transplant
The human BK polyomavirus is a significant risk factor for renal transplant dysfunction and allograft loss. The prevalence of BK viremia (BKV) following kidney transplantation is estimated to be 10-20%.
- Conditions
- Polyomavirus Infections, BK Viremia, Liver Transplant Infection, Kidney Transplant Infection
- Trial name
- NCT05224583
- Testing
- Simultaneous Liver-Kidney Transplant
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Methodist Health System
HIV Infections
Effects of Therapeutic HIV Vaccination on Control of HIV After Discontinuation of Anti-HIV Drugs
The purpose of this study is to determine whether therapeutic HIV vaccines can help the immune system control HIV viral load after anti-HIV drugs are discontinued.
- Trial name
- NCT00050063
- Testing
- Therapeutic vaccinations from A5058s
- Where
- 14 sites in United States
- Volunteers
- 78 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
EBV-induced Lymphomas, EBV-associated Malignancies
Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies
This is a Phase II trial to evaluate the efficacy and safety of human leukocyte antigen (HLA) partially-matched third-party allogeneic Epstein-Barr virus cytotoxic T lymphocytes (EBV-CTLs) for the treatment of EBV-induced…
- Conditions
- EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma
- Trial name
- NCT01498484
- Testing
- EBV-specific T cells (EBV-CTLs)
- Where
- United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Atara Biotherapeutics
Cytomegalovirus Viraemia, Stress, Physiological
Reactivation of CMV Infection in Immunocompetent Patients Under Severe Stress
Background. Human herpes viruses establish lifelong latency after primary infection and may reactivate in immunosuppressed patients causing significant morbidity and mortality.
- Conditions
- Cytomegalovirus Viraemia, Stress, Physiological, Receptor, Hormonal; Disorder, Other Deficiency of Cell-mediated Immunity
- Trial name
- RECYSTRESS (NCT01397058)
- Where
- Greece
- Volunteers
- 275 people
- Sponsor
- University of Athens
Accelerated Phase CML, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission
CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant
This phase II trial studies how well multi-peptide CMV-modified vaccinia Ankara (CMV-MVA Triplex) vaccination of stem cell donors works in preventing cytomegalovirus (CMV) viremia in participants with blood cancer undergoing…
- Conditions
- Accelerated Phase CML, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Chronic Lymphocytic Leukemia
- Trial name
- NCT03560752
- Testing
- Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
HIV-1 Infection, Treatment Resistant Disorders
Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR)
Management of participants with low-level persistent viremia
- Conditions
- HIV-1 Infection, Treatment Resistant Disorders, Viremia
- Trial name
- NCT02247687
- Testing
- Protease inhibitor, Isentress® (raltegravir), Counseling arm
- Where
- 20 sites in France
- Volunteers
- 4 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections
Alternative Dosing Strategy for Anti-HIV Drugs
Anti-HIV drugs are usually given to patients at fixed, standardized doses. This study will investigate alternative ways of dosing anti-HIV drugs to improve viral control.
- Trial name
- NCT00059384
- Testing
- Concentration-controlled therapy
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Heart Failure
HCV Positive Heart Donors
Study subjects active on the waiting list for a heart transplant at the NYU Langone Transplant Institute who are hepatitis C (HCV) negative will receive a heart transplant from a donor who tests positive for HCV.
- Trial name
- NCT03382847
- Testing
- Transplant with HCV positive donor, followed by surveillance and treatment of viremia
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- NYU Langone Health
COVID-19, SARS-CoV-2 Viraemia
Neutralizing Power of Serum Antibodies - 2
Severe forms of COVID-19 and Monkeypox affect immunocompromised and comorbid individuals. Vaccination and monoclonal antibody therapies induce neutralizing antibodies.
- Conditions
- COVID-19, SARS-CoV-2 Viraemia, Monkey Pox, Vaccination
- Trial name
- PNAS-2 (NCT07085611)
- Testing
- Sample collection (blood and optional nasal swab)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Hospitalier Régional d'Orléans
HIV, Inflammation
CC-11050 in Human Immunodeficiency Virus-1-Infected Adults With Suppressed Plasma Viremia on Antiretroviral Therapy (APHRODITE)
Background: When there is a threat to the body, the immune system triggers inflammation. Too much inflammation can damage the body or cause painful symptoms.
- Trial name
- NCT02652546
- Testing
- Assess Safety, Effect of drug on viral load, Effect of drug on T-cell count
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV/AIDS
"Switch Either Near Suppression Or THOusand"
This trial addresses the question of the viral load (VL) threshold for switching from first-line to second-line antiretroviral therapy (ART). The WHO currently sets the threshold at 1000 copies/mL.
- Trial name
- SESOTHO (NCT03088241)
- Testing
- switch
- Where
- 8 sites in Lesotho
- Volunteers
- 80 people
- Sponsor
- Niklaus Labhardt
HIV
Randomized Placebo-Controlled Trial of Atorvastatin in HIV-Positive Patients Not on Antiretroviral Therapy
This study will examine the effects of atorvastatin, a statin (drug that lowers cholesterol) on the human immunodeficiency virus (HIV).
- Trial name
- STATIN (NCT00367458)
- Testing
- Atorvastatin
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Raltegravir Intensification in HIV-infected Patients
The purpose of this study is to determine whether treatment with Raltegravir further decreases HIV viral replication in HAART-suppressed, HIV-infected patients, potentially improving immune response to antiretroviral therapy.
- Trial name
- NCT00631449
- Testing
- Raltegravir
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Francisco
Allogeneic Hematopoietic Stem Cell Transplantation, CMV Infection
CMV-TCR-T Cells for Refractory CMV Infection After HSCT
This is a single centre, single arm, open-label, phase I study to evaluate the safety and effectiveness of CMV-TCR-T cell immunotherapy in treating refractory CMV infection after HSCT.
- Trial name
- NCT05089838
- Testing
- CMV-TCR-T cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Xiao-Jun Huang
HIV
Predictors of Time to Viremia With an Analytic Treatment Interruption
This is a two-center study of 30 HIV-infected participants who have been on antiretroviral therapy (ART) for at least two years.
- Trial name
- NCT03033017
- Testing
- Blood Testing
- Where
- 2 sites in United States
- Sponsor
- University of Minnesota
Hepatitis B
Study of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients
The purpose of this clinical research study is to assess the safety and effectiveness of entecavir, when being added to lamivudine, in the treatment of adults with chronic hepatitis B infection who are co-infected with HIV.
- Trial name
- NCT00051038
- Testing
- Entecavir
- Where
- 5 sites in United States
- Sponsor
- Bristol-Myers Squibb
BK Polyomavirus, Kidney Transplant
Study of Anti-BKPyV Immune Responses in Kidney Transplant Patients With BKPyV Viremia
The human pathogen BK polyomavirus (BKPyV) is a ubiquitous, small, non-enveloped DNA virus that infects over 90% of people, typically in childhood with mild or no symptoms.
- Trial name
- NEPHRO-BK (NCT06988072)
- Testing
- blood sampling
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
BK Viremia, Kidney Transplant Infection
A Trial to Treat Polyomavirus Infections (BKPyV) in Kidney and Simultaneous Kidney Pancreas Transplant Recipients
BEAT-BK will see the effect of immunosuppression reduction/modification with and without IVIG on BKPyV infection, allograft function, allograft loss, acute transplant rejection, immunosuppression load and death in kidney and…
- Conditions
- BK Viremia, Kidney Transplant Infection, Kidney Transplant Failure and Rejection
- Trial name
- BEAT-BK (NCT05325008)
- Testing
- Immunosuppression reduction/modification + intravenous immunoglobulin, Immunosuppression reduction/modification
- Where
- 13 sites in Australia
- Volunteers
- 280 people
- Sponsor
- The University of Queensland
CMV Viremia, Heart Transplant Infection
Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant
The purpose of this study is to compare the safety and efficacy of letermovir with valganciclovir for prevention of Cytomegalovirus (CMV) viremia in moderate to high risk serostatus heart transplant recipients.
- Conditions
- CMV Viremia, Heart Transplant Infection, Heart Transplant Failure and Rejection
- Trial name
- VALET-CMV (NCT07079735)
- Testing
- Letermovir, Valganciclovir
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Columbia University